The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: Possible relevance to parkinsonism

Behavioural Brain Research

Volumn 148, Issue 1-2, 2004, Pages 47-54

  Correa, M ^a,b   Wisniecki, A ^a   Betz, A ^a   Dobson, D R ^c   O'Neill, M F ^c   O'Neill, M J ^c   Salamone, J D ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITAT JAUME I   (Spain)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Basal ganglia; Dopamine; GABA; Motor; Striatopallidal; Tremor

Indexed keywords

8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2A RECEPTOR ANTAGONIST; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENT; INJECTION; JAW MOVEMENT; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSONISM; PRIORITY JOURNAL; RAT; REARING; TREMOR;

EID: 0346365547     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(03)00178-5     Document Type: Article

References (66)

1. Alexander E.G., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
2. Aquilonius SM. Cholinergic mechanisms in the CNS related to Parkinson's disease. In: Parkinson's disease-current progress, problems and management. North Holland: Elsevier; 1980. p. 17-27.
3. Baskin P., Salamone J.D. Vacuous jaw movements in rats induced by acute reserpine administration: interactions with different doses of apomorphine. Pharmacol. Biochem. Behav. 46:1993;793-797.
4. Ben-Pazi H., Bergman H., Goldberg J.A., Giladi N., Hansel D., Reches A. et al. Synchrony of rest tremor in multiple limbs in Parkinson's disease: evidence for multiple oscillators. J. Neural Transm. 108:2001;287-296.
5. Carlson B.B., Wisniecki A., Salamone J.D. Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor. Psychopharmacology. 165:2003;229-237.
6. Carlson BB, Behrstock S, Tobin AJ, Salamone JD. Brain implantations of engineered GABA-releasing cells suppress tremor in an animal model of Parkinsonism. Neuroscience 2003 (in press).
7. Carta A.R., Pinna A., Cauli O., Morelli M. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-DOPA and A(2A) receptor blockade plus L-DOPA in dopamine-denervated rats. Synapse. 44:2002;166-174.
8. Cenci M.A., Whishaw I.Q., Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3:2002;574-579.
9. Chapman M.A., See R.E. Differential effects of unique profile antipsychotic drugs on extracellular amino acids in the ventral pallidum and globus pallidus of rats. J. Pharmacol. Exp. Ther. 277:1996;1586-1594.
10. Chen J.F., Moratalla R., Impagnatiello F., Grandy D.K., Cuellar B., Rubinstein M.et al. The role of the D2 dopamine receptor (D2R) in A2a adenosine-receptor (A2aR) mediated behavioral and cellular responses as revealed by A2a and D2 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98:2001;1970-1975.
11. Cousins M.S., Carriero D.L., Salamone J.D. Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine; effects of antiparkinsonian drugs. Eur. J. Pharmacol. 322:1997;137-145.
12. DeLong M.R. Primate model of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
13. Deuschl G., Raethjen J., Baron R., Lindemann M., Wilms H., Krack P. The pathophysiology of parkinsonian tremor: a review. J. Neurol. 247:2000;V33-V48.
14. Duvoisin R.C. Cholinergic-anticholinergic antagonism in parkinsonism. Arch. Neurol. 17:1967;124-136.
15. Ferré S., Freidholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:1997;482-487.
16. Findley LJ. Tremors: differential diagnosis and pharmacology. In: Jankovic J, Tolosa E. editors. Parkinson's disease and movement disorders. Baltimore/Munich: Urban and Schwarzenberg; 1988.
17. Finn M., Mayorga A.J., Conlan A., Salamone J.D. Involvement of pallidal and nigral GABA mechanisms in the generation of tremulous jaw movements in rats. Neuroscience. 80:1997;532-544.
18. Finn M., Jassen A., Baskin P., Salamone J.D. Tremulous characteristic of vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions. Pharmacol. Biochem. Behav. 57:1997;243-249.
19. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler E.M.et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. 14:1992;186-195.
20. Fuxe K., Ferré S., Zoli M., Agnati L.F. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Rev. 26:1998;258-273.
21. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J. et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
22. Gerfen C.R., Keefe K.A., Gauda E.B. D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons in potentiated immediate early gene response in D1-containing neurons. J. Neurosci. 15:1995;8167-8176.
23. Grimm J.W., See R.E. Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turnover as measured by dual probe microdialysis in rats. Neuroscience. 100:2000;507-514.
24. Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Prog. Neurobiol. 56:1998;507-540.
25. Hauber W., Neuscheler P., Nagel J., Muller C.E. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2a receptors in the caudate putamen of rats. Eur. J. Neurosci. 14:2001;1287-1293.
26. Hettinger B.D., Lee A., Linden J., Rosin D.L. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 431:2001;331-346.
27. Hornykiewicz O. Dopamine in the basal ganglia. Br. Med. Bull. 29:1973;172-178.
28. Jicha G., Salamone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletions: possible model of parkinsonian symptoms. J. Neurosci. 11:1991;3822-3829.
29. Kanda T., Shiozaki S., Shimada J., Suzuki F., Nakamara J. KF 17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur. J. Pharm. 256:1994;262-268.
30. Khisti R.T., Chopde C.T., Abraham E. GABAergic involvement in motor effects of adenosine A2A receptor agonist in mice. Neuropharmacology. 39:2000;1004-1015.
31. Keppel G, Zedeck S. Data analysis for research designs. New York: W.H. Freeman and Co.; 1989.
32. LeMoine C., Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of dorsal and ventral striatum. J. Comp. Neurol. 355:1995;418-426.
33. Mally J., Stone T.W. The effect of theophylline on parkinsonian symptoms. J. Pharm. Pharmacol. 46:1994;515-517.
34. Mally J., Stone T.W. Potential of adenosine A2A antagonists in the treatment of movement disorders. CNS Drugs. 10:1998;311-320.
35. Marsden C., Duvoisin R., Jenner P., Parkes J., Pycock C., Tarsy D. Relationship between animal models and clinical parkinsonism. Adv. Neurol. 9:1975;165-175.
36. 1 mechanisms involved in the antiparkinsonian effects of SKF 82958 (APB): studies of tremulous jaw movements in rats. Psychopharmacology. 143:1999;72-81.
37. McEvoy J.P. The clinical use of anticholinergic drugs as treatments for extrapyramidal side effects of neuroleptic drugs. J. Clin. Psychpharmacol. 3:1983;288-302.
38. McSwain M.L., Forman L.M. Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol. J. Clin. Psychopharmacol. 15:1995;284.
39. Morelli M., Pinna A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol. Sci. 22:2001;71-72.
40. Müller C.E., Sauer R., Maurish Y., Fülle F., Nagel J., Hauber W. Water-soluble prodrug of potent A2A-selective adenosine receptor antagonists. Drug Dev. Res. 45:1998;190-197.
41. Murray T.K., Messenger M.J., Ward M.A., Woodhouse S., Osborne D.J., Duty S.et al. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol. Biochem. Behav. 73:2002;455-466.
42. Nash J.E., Brotchie J.M. A common signalling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J. Neurosci. 20:2000;7782-7789.
43. Noring U., Povlesen U.J., Casey D.E., Gerlach J. Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism. Psychopharmacology. 84:1984;569-571.
44. Ochi M., Koga K., Kurokawa M., Kase H., Nakamura J., Kuwana Y. Systemic administration of adenosine A(2a) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience. 100:2000;53-62.
45. Rodriguez Diaz M., Abdala P., Barroso-Chinea P., Obeso J., Gonzalez-Hernandez T. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav. Brain Res. 122:2001;79-92.
46. Rupniak N.M., Jenner P., Marsden C.D. Acute dystonia induced by neuroleptic drugs. Psychopharmacology. 88:1986;403-419.
47. Salamone J.D., Lalies M.D., Channell S.L., Iversen S.D. Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacology. 88:1986;467-471.
48. Salamone J.D., Johnson C.J., McCullough L.D., Steinpreis R.E. Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology. 102:1990;529-534.
49. Salamone J.D., Baskin P. Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor. Pharmacol. Biochem. Behav. 53:1996;179-183.
50. Salamone J.D., Cousins M.S., Maio C., Champion M., Turski T., Kovach J. Different behavioral effects of haloperidol, clozapine and thioridazine in a concurrent level pressing and feeding procedure. Psychopharmacology. 125:1996;105-112.
51. Salamone J.D., Mayorga A.J., Trevitt J.T., Cousins M.S., Conlan A., Nawab A. Tremulous jaw movements in rats; a model of parkinsonian tremor. Prog. Neurobiol. 56:1998;591-611.
52. Salamone J., Correa M., Carlson B., Wisniecki A., Mayorga A., Nisenbaum E.et al. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents. Implications for cholinergic involvement in parkinsonism. Life Sci. 68:2001;2579-2584.
53. Schiffman S.N., Jacobs O., Vanderhaeghen J.J. The striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephaline but not by substance P neurons: an in-situ hybridization study. J. Neurochem. 57:1991;1062-1067.
54. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K., Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. 147:1999;90-95.
55. Steinpreis R.E., Baskin P., Salamone J.D. Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine. Psychopharmacology. 111:1993;99-105.
56. Steinpreis R.E., Salamone J.D. Effects of acute haloperidol and reserpine administration on vacuous jaw movements in three different age groups of rats. Pharmacol. Biochem. Behav. 46:1993;405-409.
57. Stromberg I., Popoli P., Muller C.E., Ferre S., Fuxe K. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in dopamine-denervated striatum. Eur. J. Neurosci. 12:2000;4033-4037.
58. Svenningsson P., Le Moine C., Fisone G., Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59:1999;355-396.
59. Trevitt J., Atherton A., Aberman J., Salamone J.D. Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function in the rat. Psychopharmacology. 137:1998;61-66.
60. Trevitt J.T., Carlson B.B., Correa M., Keene A., Morales M., Salamone J.D. Interactions between D1 receptors and GABA mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies. Psychopharmacology. 159:2002;229-237.
61. Wang W.F., Ishiwata K., Nonaka H., Ishii S., Kiyosawa M., Shimada J.et al. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. Nucl. Med. Biol. 27:2000;541-546.
62. Wardas J., Konieczny J., Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse. 41:2001;160-171.
63. A antagonism in globus palidus: studies of locomotion and tremulous jaw movements. Psychopharmacology 2003 (in press).
64. Wichmann T., Kliem M., Delong M. Antiparkinsonian behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian monkeys. Exp. Neurol. 167:2001;410-424.
65. Worms P., Lloyd K.G. Biphasic effects of direct, but not indirect, GABA mimetics and antagonists on haloperidol-induced catalepsy. Naunyn Schmiedebergs Arch. Pharmacol. 311:1980;179-184.
66. Young AB, Penney JB. Biochemical and functional organization of the basal ganglia. In: Jankowic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams and Wilkins; 1993. p. 1-12.